News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Business
Microbix Biosystems Inc. Signs Letters of Intent to License its Flu Vaccine Yield Enhancement Technology
December 14, 2007
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
TORONTO, Dec. 14 /CNW/ - Microbix Biosystems Inc. (TSX:MBX) has signed two Letters Of Intent with companies outside North America which are interested in licensing the VIRUSMAX(TM) technology on a non-exclusive basis.
Twitter
LinkedIn
Facebook
Email
Print
Alliances
MORE ON THIS TOPIC
Layoff Tracker
Sensei Plans to Cut Workforce While Considering Strategic Alternatives
November 3, 2025
·
77 min read
·
BioSpace Editorial Staff
Mergers & acquisitions
UPDATE: Pfizer Files Lawsuits Against Novo Nordisk, Metsera To Stop Rival Bid
November 3, 2025
·
4 min read
·
Tristan Manalac
Editorial
Novo’s CEO Doesn’t Seem To Mind Being Big Pharma’s Villian
October 31, 2025
·
3 min read
·
Annalee Armstrong
Earnings
AbbVie’s Immunology Dyad Dominates Again in Q3
October 31, 2025
·
2 min read
·
Dan Samorodnitsky